http://www.tucc.com Clinical advancements in the field of urology are featured in the news media every day. This RSS feed provides patients and physicians with the most up-to-date information on recent urologic advancements around the world. Wed, 19 Jun 2013 04:34:45 GMT http://www.tucc.com/Olive-Oil-and-Nuts-Tied-to-Prostate-Cancer-Survival-.29.525.html Sometimes, it doesn't take a major diet overhaul to get significant health benefits. Small changes can be helpful, too. This seems to be the take-home message from a new study in JAMA Internal Medicine linking olive oil and nuts to improved survival from prostate cancer. Researchers studied the fat intake of more than 4,500 men who had been diagnosed with non-metastatic prostate cancer (this is cancer that's still confined to the prostate gland and has not spread to another place in the body). Wed, 12 Jun 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/Sleep-Disruption-Among-Older-Men-and-Risk-of-Prostate-Cancer.29.524.html Our data suggest that certain aspects of sleep disruption may confer an increased risk of prostate cancer and call for additional, larger studies with longer follow-up times. Fri, 07 Jun 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/Adding-Curcuminoids-to-Docetaxel-Shows-Promise-in-Castrate-Resistant-Prostate-Cancer.29.523.html Addition of curcuminoids to treatment with docetaxel was well tolerated and showed promise in improving the response rate to docetaxel “in terms of both PSA decrease and objective response” in a phase II trial in patients with castration-resistant prostate cancer (CRPC). Findings were reported by Hakim Mahammedi, MD, of Centre Jean Perrin, Clermont-Ferrand, France. Mahammedi and colleagues will formally present the findings during the annual meeting of the European Society for Medical Oncology in Amsterdam, September 27–October 1. Wed, 05 Jun 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/Brachytherapy-a-good-option-for-younger-prostate-cancer-patients-.29.522.html Brachytherapy (BT) provides excellent long-term outcomes for relatively young men with clinically localized prostate cancer (PCa), researchers reported. In a study of 236 men aged 60 years or younger with clinically localized PCa, BT alone or in combination with external beam radiation therapy (EBRT) was associated with eight-year PSA relapse-free survival (RFS), cancer-specific survival, and overall survival rates of 96%, 99%, and 96%, respectively, according to findings published in BJU International (2013;111:1231-1236). BT-based approaches also were associated with a low risk of long-term genitourinary  (GI) and gastrointestinal (GI) morbidities, with erectile function preserved in more than half of patients. Mon, 03 Jun 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/First-man-has-prostatectomy-because-of-BRCA-gene-mutation-.29.521.html The first man has undergone prostatectomy after finding that out that he carries the BRCA2 gene mutation. BRCA gene mutations increase the risk for a number of cancers, including prostate cancer. They were in the news last week after superstar Angelina Jolie announced that she had a prophylactic mastectomy to avoid breast cancer. Hot on the heels of that extensive media coverage, news of the first prophylactic prostatectomy because of the genetic mutation made the front page of the Sunday Times. Fri, 24 May 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/2-Radiotherapy-Treatments-Show-Similar-Morbidity-Cancer-Control-After-Prostatectomy.29.520.html Use of the newer, more expensive intensity-modulated radiotherapy (IMRT) and use of the older conformal radiotherapy (CRT) after surgical removal of all or part of the prostate gland were associated with similar morbidity and cancer control outcomes, according to a study published Online First by JAMA Internal Medicine, a JAMA Network publication. Wed, 22 May 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/FDA-Approves-New-Drug-Xofigo-to-Treat-Prostate-Cancer.29.519.html A new drug 'Xofigo' has been approved by the U.S. Food and Drug Administration to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has attacked the bones but not other organs. Bayer and Algeta's drug  'Xofigo' (radium Ra 223 dichloride) is meant for men in who the cancer has spread after undergoing medical and surgical therapy to lower testosterone levels. Thu, 16 May 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/Bone-targeted-therapies-evolve-in-prostate-cancer.29.518.html The treatment of bone metastases in prostate cancer has changed over the years, and several options are now either available or under development. Daniel P. Petrylak, MD, director of the Genitourinary Oncology Program at Yale Cancer Center in New Haven, Connecticut, spoke about advances in bone-targeted therapy at the 6th Annual Interdisciplinary Prostate Cancer Congress, which was held in New York City on March 16. “Bisphosphonates used to be the only option,” he said, “but treatment has evolved over the years.” Bone resorption and bone formation are dysregulated in prostate cancer, and clinical evidence indicates that both processes contribute to bone metastases. The mechanisms for bone metastases are complex, and include tumor stimulation of osteoclasts and osteoblasts, and the response of the bone microenvironment. In addition, factors independent of the tumor may contribute to bone resorption. Mon, 13 May 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/New-test-improves-assessment-of-prostate-cancer-risk-study-says.29.517.html A new test can help distinguish aggressive prostate cancer from less threatening ones, potentially saving many men from unneeded operations for tumors that would never hurt them, researchers are reporting. The test, developed by Genomic Health, could triple the number of men who could confidently monitor their tumors rather than undergo surgery or radiation treatments, according to the company and to researchers. Fri, 10 May 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/AUA-Many-men-with-erectile-dysfunction-untreated.29.516.html Only about a quarter of men diagnosed with erectile dysfunction (ED) receive treatment, despite the availability and heavy media promotion of treatments, according to a study presented at the annual meeting of the American Urological Association. Thu, 09 May 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/Clinical-Evaluation-of-Treatment-with-Peyronies-Disease-with-Collagenase-Clostridium-Histolyticum.30.515.html TUCC physicians and clinical investigators Lawrence Karsh, M.D., and Jesse Mills, M.D., presented the results of a national clinical evaluation of the treatment of Peyronie’s Disease at the American Urological Association 2013 Annual Meeting. Three phase 3 studies have been conducted to examine the safety and efficacy of collagenase clostridium histolyticum (CCH) in subjects with Peyronie’s disease (PD). The effect of CCH on change in penile curvature deformity from baseline to end of study was analyzed by the subjects’ duration of disease or degree of plaque calcification. Treatment with CCH resulted in improvements in curvature deformity regardless of duration of disease or level of plaque calcification; although small differences were noted within the subgroups, they are not expected to be clinically meaningful. Tue, 07 May 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/BPH-Drug-Prescribing-Increasing-in-the-US.29.514.html Physicians in the U.S. increasingly have been prescribing pharmacotherapy to treat lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH), according to data from two studies presented at the American Urological Association annual meeting. Sun, 05 May 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/Personal-Epigenetic-Signatures-Found-Consistent-in-Prostate-Cancer-Patients-Metastases.29.513.html In a genome-wide analysis of 13 metastatic prostate cancers, scientists at the Johns Hopkins Kimmel Cancer Center found consistent epigenetic “signatures” across all metastatic tumors in each patient. The discovery of the stable, epigenetic “marks” that sit on the nuclear DNA of cancer cells and alter gene expression, defies a prevailing belief that the marks vary so much within each individual’s widespread cancers that they have little or no value as targets for therapy or as biomarkers for treatment response and predicting disease severity. Tue, 30 Apr 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/Data-support-robot-assisted-partial-nephrectomy-for-kidney-cancer.29.512.html Robot-assisted partial nephrectomy (RPN) is associated with intermediate-term oncologic and renal function outcomes equivalent to those of laparoscopic and open partial nephrectomy, according to a new study. Jihad H. Kaouk, MD, and colleagues at Cleveland Clinic's Glickman Urological and Kidney Institute reviewed outcomes of 134 patients who underwent RPN and who had a minimum of two years of follow-up. Of these, 70 had at least three to six years of follow-up. The cohort had a mean age of 59 years and a mean body mass index of 29.8 kg/m2. The mean tumor size based on computed tomography scans was 3 cm. Sun, 28 Apr 2013 07:00:00 GMT http://www.tucc.com http://www.tucc.com/Prostate-cancer-Call-to-test-men-in-their-40s-.29.511.html Men should be offered a screening test for prostate cancer in their late 40s, researchers say. The idea is controversial as prostate specific antigen (PSA) testing can be unreliable, throwing up false positive results that can cause undue worry and even treatment over something benign. But the Swedish team say checking every man aged 45-49 would predict nearly half of all prostate cancer deaths. Wed, 17 Apr 2013 07:00:00 GMT http://www.tucc.com